Price cap on cancer drugs increase to tackle shortage
The ceiling rate for cisplatin was raised to ₹10.89 per ml from ₹7.26, while that for carboplatin was increased to ₹90.74 per ml from ₹60.49 excluding taxes
Impacted Stocks
CIPLA — Cipla
▲ Bullish +0.1219%Cipla is directly named as a key manufacturer of cisplatin and carboplatin formulations in India. The 50% upward revision in ceiling prices by the NPPA fundamentally restores gross margins that were completely eroded by a multi-year surge in platinum raw material costs. This regulatory relief enables the company to resume halted production and fully pass on escalated API input expenses to the market, triggering a positive multi-day tactical re-rating for its oncology division.
Track these stocks in your portfolio
Get instant alerts the next time news breaks on stocks you own — free on Android.
Download Investonks Free →